Recent Updates
Recently added Catalysts

Acute Ischemic Stroke: two biotech companies racing to a treatment

Neurology & PsychiatryConcentrated betData as of 2026-09-04

Competitors2in the clinic
Median market cap$1.3Buniverse median $1.20B
Allocated capital$486M$2.6B competing
Phase 3 or filed11 mid, 0 early
Pure plays0this indication only
Capital rank202/299crowding rank 97

Acute Ischemic Stroke is a two-horse race: HUTCHMED (China) (HCM, $2.5B) against Milestone Pharmaceuticals (MIST, $151M).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $486M of allocated capital sits on the pair.

HCM alone accounts for 94% of the $2.6B of market capitalisation competing here, so this is a leader plus a tail rather than a level race.

$486M of allocated capital sits in Acute Ischemic Stroke, ranking it 202nd of 299 indications by the money committed to it.

Companies developing drugs for Acute Ischemic Stroke 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
HCMHUTCHMED (China)SHPL-49Phase 31$2.5BNo6No dated event
MISTMilestone PharmaceuticalsJX10Phase 21$151MNo2No dated event

Sorted by phase, then by market capitalisation. Ticker links open the company profile. HCM holds 94% of the $2.6B competing in this indication.

Why Acute Ischemic Stroke is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Acute Ischemic Stroke has 2 competitors and a median of $1.3B.

Neurology & Psychiatry

Neurology & Psychiatry holds $120B of the map's capital, 17.9% of the total, spread across 46 indications and 58 companies. 19 of those indications have more than one company competing.

See every Neurology & Psychiatry indication on the map

Related indications in Neurology & Psychiatry

Major Depressive Episode1 company · $426M · median $1.3BUncontestedPrimary Erythromelalgia1 company · $342M · median $2.4BUncontestedEpilepsy1 company · $639M · median $2.6BUncontestedCervical Spinal Cord Injury1 company · $278M · median $278MUncontestedOsteoarthritis Knee Pain1 company · $265M · median $1.1BUncontestedAcute Postoperative Pain1 company · $265M · median $1.1BUncontestedPostoperative Pain1 company · $265M · median $1.1BUncontestedFrontotemporal Dementia1 company · $729M · median $3.6BUncontested

Acute Ischemic Stroke pipeline questions

Which biotech companies are developing drugs for Acute Ischemic Stroke?

HUTCHMED (China) (HCM, SHPL-49, Phase 3); Milestone Pharmaceuticals (MIST, JX10, Phase 2). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Acute Ischemic Stroke.

How advanced is the Acute Ischemic Stroke pipeline?

Of the 2 clinical-stage programmes in Acute Ischemic Stroke, 1 is in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Which company leads the Acute Ischemic Stroke field?

HCM is the largest developer in Acute Ischemic Stroke, holding 94% of the $2.6B of market capitalisation competing in the indication. The median competitor is worth $1.3B.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map